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Summary Allelic losses on chromosome 16q in tumour cells are frequent in a variety of malignancies, suggesting the presence of one or
more tumour-suppressor genes in the region. Among 210 sporadic breast cancers we examined using 15 microsatellite markers on the long
arm of chromosome 16, heterozygosity for at least one locus was lost in 141 (67%). Detailed deletion mapping revealed two distinct commonly
deleted regions. One region was defined as a 3-cM interval flanked by markers D16S512 and D16S515 at 16q22; the second consisted of a
9.5-cM interval flanked by markers D16S498 and D16S303 at q24.3. Allelic loss on 16q was observed frequently in small tumours, tumours
without lymph node metastasis and tumours of the non-invasive histological type as well as in tumours of more advanced phenotype,
suggesting that inactivation of one of at least two tumour-suppressor genes on 16q plays a role in early stage breast carcinogenesis.
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INTRODUCTION
Human carcinomas are now considered to develop through the
accumulation of genetic changes within a cell lineage. Several
genetic alterations that activate oncogenes (c-myc, erbB-2, int2)
and/or inactivate known tumour-suppressor genes (p53, Rb) have
been documented in breast cancers. Frequent observations of loss
of heterozygosity (LOH) at specific chromosomal loci in human
tumours are generally understood to signal the presence of
tumour-suppressor genes in the affected chromosomal regions. We
have demonstrated frequent LOH on chromosomes 3p, 1p, 13q,
16q, 17p and 17q in human breast cancers (Sato et al, 1990, 1991;
Takita et al, 1992; Saito et al, 1993; Harada et al, 1994; Ito et al,
1995). It appears that a variety of tumour-suppressor genes may
influence the development and progression ofbreast cancer.
LOH occurs frequently on 16q in hepatocellular carcinomas
(HCCs) and prostate cancers as well as in breast cancers (Carter et
al, 1990; Tsuda et al, 1990). Tsuda and Hirohashi (1995) and
Radford et al (1995) found evidence that the putative tumour-
suppressor gene(s) on 16q may be involved in early stage breast
carcinogenesis. To define more precisely the location(s) of such
genes, we examined 210 primary breast cancers and constructed a
detailed deletion map ofchromosome 16q.
MATERIALS AND METHODS
Samples and DNA preparation
DNAs were extracted from frozen tissue samples as described previ-
ously (Sato et al, 1990). Tumours were classified by pathologists
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according to the histological primary tumour, regional lymph nodes
and distant metastases (TNM) classification and the histological
typing scheme of the Japanese Breast Cancer Society, into the
following types: non-invasive tubular (la), invasive papillotubular
(al), invasive solid tubular (a2), invasive scirrhous carcinoma (a3)
and other specific types (b group). This classification is essentially
the same as the World Health Organization scheme for typing breast
tumours. Oestrogen receptor (ER) and progesterone receptor
(PgR) were measured by radioreceptor assay in a strand dextran-
coated charcoal (DCC) method, using [1251] oestradiol as labelled
ligand on homogenates of individual fresh-frozen tissues (Otsuka
Pharmaceutical Co.). All samples containing > 5fmol ofER or PgR
mg-' protein were considered receptor positive.
LOH analysis
Fifteen polymorphic microsatellite markers (D16S401, D16S419,
D16S408, D16S514, D16S512, D16S515, D16S518, D16S504,
D16S507, D16S511, D16S402, D16S520, D16S498, D16S413,
D16S303) were used in this study (Thompson et al, 1992; Gyapay
et al, 1994; Kozman et al, 1995; Durocher et al, 1995, Callen et al,
1995). Each was amplified by the polymerase chain reaction
(PCR) in 10-,ul volumes of mixture containing lx PCR buffer
(30 mM Tris-HCl pH8.8, 50 mm potassium chloride, 2 mm magne-
sium chloride, 5 mm P-mercaptoethanol), 200 JtM each dNTP,
2 pmol each of unlabelled primer and primer labelled with [,y32p]-
ATP, 50 ng of genomic DNA and 0.25 U of Taq polymerase
(Boehringer Mannheim). Each PCR was performed in 25 cycles
under the following conditions: 94°C for 30 s, 50-650C for 30 s
and 720C for 30 s (Gene Amp PCR 9600 System, Perkin-Elmer
Cetus, Norwalk, CT, USA). Loading buffer (10 tl) was added to
each reaction, and the samples were denatured. Auquots of 5 ,tl of
each solution were electrophoresed in a 6% polyacrylamide gel
containing 7.7 M formamide, for 4-5 h at 1500-2000 V. Gels were
dried and exposed to Fuji X-ray film for 24-48 h. Signal intensities
of the polymorphic alleles were quantified by a Hoefer GS-300
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Table 1 LOH at loci on chromosome 16 among 210 breast cancers
Location on Number of LOH/
Locus ch16 informative informative
patients cases (%)
D16S401 p12-p13 143 40 (28)
D16S419 q12-q13 94 42 (45)
D16S408 q12-q13 131 58 (44)
D16S514 q21-q22 130 70 (54)
D16S512 q22 137 84 (61)
D16S515 q22 164 100 (61)
D16S518 q22-q23 125 77 (62)
D16S504 q22-q23 131 82 (63)
D16S507 q23-q24 115 65 (57)
D16S511 q23-q24 156 84 (54)
D16S402 q23-q24 143 85 (59)
D16S520 q24.3 158 96 (61)
D16S498 q24.3 116 71 (61)
D16S413 q24.3 138 90 (65)
D16S303 q24.3 41 18 (44)
210 141 (67)
scanning densitometer; peak areas corresponding to each signal
were calculated by electric integration using the GS-370 elec-
trophoresis data system (Hoefer Scientific Instruments, San
Francisco, CA, USA). Signal intensities ofalleles in tumour-tissue
DNA samples were compared with those of DNAs from corre-
sponding normal tissues. Wejudged reductions in signal intensities
>50% to indicate LOH, and distinguished LOH from chromosome
multiplication by normalizing each signal to the signal obtained
when the same DNA was analysed with markers for loci on other
chromosomes.
RESULTS
Our panel of 15 microsatellite markers on chromosome 16q
detected LOH with at least one marker in 141 (67%) of210 breast
cancers. Table 1 lists the marker loci in descending order from
16pl2-13 to 16qter, according to mapping data reported by
Thompson et al (1992), Gyapay et al (1994), Kozman et al (1995),
Durocher et al (1995) and Callen et al (1995), and shows their
frequencies of LOH in the breast tumours examined. LOH was
observed most frequently at D16S518 (62%) at q22 and at
D16S413 (65%) on q24.3. Among the 141 tumours that had lost an
allele for at least one locus, 59 showed LOH at all loci tested,
suggesting loss of the whole chromosomal arm; the other 82
showed a pattern ofpartial or interstitial deletion of 16q.
Representative autoradiograms ofcases that revealed interstitial
deletions ofthe 16q22 region are presented in Figure IA. Tumour
512 showed LOH at D16S512, whereas two flanking loci,
D16S514 and D16S515, retained heterozygosity. Tumour 710
showed LOH for D16S515, but retained heterozygosity for
D16S512 and D16S518. Figure lB shows representative autoradi-
ograms of cases that exhibited interstitial or telomeric deletion of
16q24.3. Tumour 152 showed LOH at D16S520 but retained
heterozygosity at D16S402 and S16S303. Tumour 166 showed
LOH at D16S413 but retained D16S498.
Ofthe 82 tumours that showed partial or interstitial deletions of
16q, the 13 represented in Figure 2A as a deletion map showed
deletions at or around 16q22. These cases were used to define a
commonly deleted region. The proximal limit of that region was
defined by D16S512, on the basis of observations in two tumours
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Figure 1 Representative autoradiograms of microsatellite markers examined
for LOH. N and T, normal and tumour DNAs respectively, from patients 512,
710, 152 and 166. Marker loci are given below each autoradiogram
(246 and 710) that retained heterozygosity at D16S512 while
showing LOH at more distal loci. The distal limit was defined by
D16S515; four tumours (252, 512, 788 and 794) retained
heterozygosity with D16S515 while showing LOH at more prox-
imal loci. Hence, the commonly deleted region was localized to a
3-cM interval flanked by D16S512 and D16S515. Figure 2B
shows seven cases that exhibited deletions only at or around
16q24. This distal common region of deletion was confined to a
9.5-cM interval flanked by D16S498 and D16S303 at 16q24.3.
We also compared LOH on 16q with clinicopathological para-
meters including tumour size and infiltration, lymph node metas-
tasis, ER status, PgR status and histopathological classification
(Table 2). The frequency of LOH was not significantly different
from one clinicopathologically defined group to another, and
LOH on 16q was not specifically associated with any of these
parameters.
DISCUSSION
Loss of chromosome 16 is one of the most frequent cytogenetic
abnormalities observed in primary breast cancers. We present here
the results of high-resolution deletion mapping of 210 breast
cancers using 15 microsatellite markers on 16q. We identified two
target regions of common deletion on 16q in breast cancers. The
more proximal of these regions was defined in a 3-cM interval
between D16S512 and D16S515 at 16q22; the other was defined
in a 9.5-cM interval between D16S498 and D16S303 at 16q24.3.
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Figure 2 Deletion mapping of chromosome 16. (A) 16q22 region. (B) 16q24 region. Case numbers are shown above each map; marker names appear on the
linkage map at left. 0 LOH; 0 retained heterozygosity; blank spaces, not informative. Commonly deleted regions are shown by heavy marks at the right of each
panel and are outlined by rectangles superimposed on the maps
Table 2 Correlation between LOH on chromosome 16q and clinical
parameters
16q
LOH (+) LOH (-)
t factor
tla 38 17
t2a 82 41
t3a 15 3
Lymph node metastasis
n (_)b 61 38
n (+)b 74 26
ER
Positive 71 29
Negative 50 27
PgR
Positive 85 36
Negative 35 20
Histological type
1a,c Intraductal carcinoma 2 4
al,c Papillotubular carcimoma 29 10
a2,cSolid tubular carcinoma 38 19
a3,c Scirrhous carcinoma 56 22
aTNM classification of the Japanese Breast Cancer Society.
bn(-), case without lymph node metastasis; n(+), case with lymph node
metastasis.
cHistological classification of breast cancer of the Japanese Breast Cancer
Society.
Cleton-Jansen et al (1994) also described two commonly
deleted regions in breast cancers, one between D16S398 and
D16S301 and a more distal region between APRT and D16S303.
APRT is located distal to D16S413 and proximal to D16S303.
Although located close to one another, the more proximal ofthese
regions did not correspond to the one we defined at 16q22 in the
present study. A more detailed mapping study will be necessary to
clarify a relationship between the results ofthe two studies.
LOH of 16q has been observed frequently in HCCs (Tsuda et al,
1990) and in prostate cancers as well (Carter et al, 1990). The
common region ofdeletion described in HCC was located within a
16-cM interval between HP and CTRB at q22.1-q23.2. HP is
located distal to D16S514. CTRB is located in an interval flanked
by D16S515 and D16S402. The proximal target we defined in
breast cancers falls within the same region.
Reduced expression or mutation in the E-cadherin gene on chro-
mosome 16q22 has been described in a few cases of a rare type of
human breast cancer, lobular carcinoma (Kanai et al, 1994; Berx et
al, 1995). The majority ofthe cancers analysed in the present study
belongs to a more common type of carcinoma, ductal carcinoma.
No mutation of the E-cadherin gene has been described in this
type. Moreover, the E-cadherin gene was found to be more prox-
imal to the commonly deleted region and was excluded from a list
ofcandidate genes through our deletion mapping analysis.
The region deleted most frequently in breast cancers is at
16q24.3 (Cleton-Jansen et al, 1994; Tsuda et al, 1994; Skirnisdottir
et al, 1995). We also detected frequent LOH at this region in the
study reported here: >60% at D16S520, D16S498 and D16S413.
Together, the data suggest that a putative tumour-suppressor gene
for breast cancer exists within a 9.5-cM interval at 16q24.3.
Radford et al (1995) found frequent LOH on 16q and 17p in
preinvasive ductal carcinomas in situ, and provided evidence that
British Journal ofCancer (1997) 75(2), 264-267
A B
0 CancerResearch Campaign 1997Deletion mapping ofch. 16q22 in breast cancers 267
loss of 16q is associated with breast tumorigenesis before progres-
sion to invasive cancer. In the present study, LOH on 16q was
observed frequently in small tumours, tumours without lymph
node metastasis and tumours of non-invasive histological type as
well as in tumours of more advanced phenotype. Tsuda et al
(1994) also observed frequent LOH on 16q in tumours of low or
moderate histological grade of atypia as well as in those of a
higher grade ofatypia. All these data are consistent with the notion
that LOH on 16q is an early event in breast carcinogenesis, and
they suggest that inactivation of one or more tumour-suppressor
genes on this chromosome is responsible.
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